LifeVantage reported second quarter revenue of $48.9 million, down 27.8% year-over-year and up 2.9% sequentially. Revenue in the Americas fell 32.6%, while Asia/Pacific & Europe declined 2.1% (3.7% on a constant currency basis). Gross profit was $36.2 million (74.0% of revenue), compared with $54.6 million (80.5%) a year earlier; adjusted non-GAAP gross profit was $38.6 million (78.8%). Commissions and incentives expense totaled $19.9 million (40.7% of revenue), and SG&A was $15.8 million (32.3%). Operating income was $0.5 million, versus $3.4 million in Q2 FY 2025; adjusted non-GAAP operating income was $2.6 million. Net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19; adjusted non-GAAP net income was $1.9 million, or $0.15 per share, versus $3.0 million, or $0.22. Adjusted EBITDA was $3.9 million, down from $6.5 million.

Through the first half of FY 2026 LifeVantage generated $0.5 million in cash from operations, compared to $8.6 million a year ago. Cash and equivalents stood at $10.2 million as of December 31, 2025, down from $20.2 million at June 30, 2025; no debt is outstanding. The company repurchased 44,000 shares for $0.6 million during the period and launched a new $60 million share buyback program extending through December 31, 2027. A quarterly cash dividend of $0.045 per share was declared, payable March 16, 2026 to holders of record as of March 2.

LifeVantage expects full-year fiscal 2026 revenue of $185 million to $200 million, adjusted EBITDA of $15 million to $19 million, and adjusted EPS of $0.60 to $0.80. The company anticipates a full-year effective tax rate of approximately 22%–24%. Guidance excludes any non-operating or non-recurring items and reflects planned international expansion, new product launches (including LoveBiome extensions), and continued investment in the MindBody GLP-1 System.

Steve Fife, President and Chief Executive Officer for nine years, will retire in April 2026. He will remain in his roles through the transition to ensure continuity. Raymond Greer, Chairman, noted that comprehensive succession planning has been under way and the board expects to announce the new CEO in the coming months. Fife highlighted the company’s evolution of its business model, strengthening of market position and expressed confidence in the leadership team as LifeVantage enters its next phase of growth.